Yervoy (ipilimumab) / Ono Pharma, BMS 
Welcome,         Profile    Billing    Logout  

556 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yervoy (ipilimumab) / BMS
2014-004420-22: Treatment of skin cancer using a different approach than surgery using an electroporation device that makes the tumour absorb more drug while leaving the healthy tissue alone combined with an immune modulator that enhances the anti-tumour immune response.

Ongoing
4
10
Europe
Ipilimumab, L01XC11, Powder for solution for injection, 1. Yervoy
University College Cork, University College Cork, Bristol Myers Squibb
Advanced Melanoma Cancer, Advanced Melanoma Cancer, Diseases [C] - Cancer [C04]
 
 
2016-001925-15: Effects of a treatment with Denosumab, applied together with either Nivolumab oder Pembrolizumab, in patients with skin cancer and bone metastases Effekte einer Behandlung mit Denosumab in Kombination mit etnweder Nivolumab oder Pembrolizumab auf Patienten mit Hautkrebs und Knochenmetastasen

Not yet recruiting
4
20
Europe
DENOSUMAB, OPDIVO, KEYTRUDA, YERVOY, Solution for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, XGEVA
Alcedis GmbH, Amgen GmbH
Metastatic malignant melanoma Metastasiertes malignes Melanom, Skin cancer with bone metastases Hautkrebs mit Knochenmetastatsen, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2022-002673-28: Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab Safe Stop IPI-NIVO Trial: Vroegtijdige stopzetting van nivolumab bij het bereiken van een (bevestigde) volledige of gedeeltelijke respons bij patiënten met irresectabel stadium III of gemetastaseerd melanoom behandeld met eerstelijns ipilimumab-nivolumab

Not yet recruiting
4
80
Europe
ipilimumab, nivolumab, pembrolizumab., Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, YERVOY, OPDIVO, KEYTRUDA
Erasmus MC, Erasmus MC
Stage III irresectable or metastatic melanoma treated with first-line ipilimumab-nivolumab Stadium III irresectabel of gemetastaseerd melanoom behandeld met eerstelijns ipilimumab-nivolumab, Stage III irresectable or metastatic melanoma treated with first-line ipilimumab-nivolumab Stadium III irresectabel of gemetastaseerd melanoom behandeld met eerstelijns ipilimumab-nivolumab, Diseases [C] - Cancer [C04]
 
 
CheckMate 7C9, NCT04513522: A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

Completed
4
101
RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb
Kidney Neoplasms
01/24
01/24
MINUTE, NCT06031233: Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting
4
679
Europe
Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab, Bevacizumab, Trastuzumab
Isala
Oncology, Infusion Reaction
07/24
12/24
Ipi4, NCT02068196 / 2013-002408-15: A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

Active, not recruiting
4
150
Europe
Blood sampling for Pre-existing immunity, Ipilimumab
Oslo University Hospital
Malignant Melanoma
12/25
12/26
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
CheckMate 067, NCT01844505 / 2012-005371-13: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma

Checkmark Data from P3 CheckMate 067 trial in 1L advanced melanoma
Sep 2021 - Sep 2021: Data from P3 CheckMate 067 trial in 1L advanced melanoma
Checkmark From CheckMate 067 trial in combination with Yervoy for melanoma at ASCO 2021
Jun 2021 - Jun 2021: From CheckMate 067 trial in combination with Yervoy for melanoma at ASCO 2021
Checkmark Six and half year follow-up data from CheckMate 067 study in combination with Yervoy for advanced melanoma at ASCO 2021
More
Active, not recruiting
3
1296
Europe, Canada, US, RoW
Nivolumab, BMS-936558, MDX-1106, Ipilimumab, Yervoy, BMS-734016, MDX-010, Placebo for Nivolumab, Placebo for Ipilimumab
Bristol-Myers Squibb
Unresectable or Metastatic Melanoma
08/16
10/24
2016-005197-35: A clinical trial to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab for patients with melanoma that has been successfully treated with surgery but has a high probability of coming back.

Not yet recruiting
3
1378
Europe
Pembrolizumab, Interferon alfa-2b, MK-3475, Solution for infusion, Solution for injection/infusion, KEYTRUDA®, IntronA
Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland, SWOG
High risk resected melanoma., Melanoma, which, although it has been successfully treated with surgery, has a high probability of coming back., Diseases [C] - Cancer [C04]
 
 
CheckMate 214, NCT02231749 / 2014-001750-42: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Checkmark Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CheckMate 214 trial in advanced Sarcomatoid RCC at IKCS 2022
Checkmark Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Jan 2022 - Jan 2022: Additional data following 42-month period in combination with Yervoy in advanced 1L RCC from CheckMate 214 study
Checkmark Additional data following 42 month randomization from CheckMate-214 trial for advanced 1L RCC
More
Active, not recruiting
3
1390
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, Sunitinib, Sutent
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
06/17
08/27
CheckMate 238, NCT02388906 / 2014-002351-26: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Hourglass Oct 2023 - Oct 2023 : Seven-year efficacy results from P3 CheckMate-238 trial of adjuvant Opdivo in resected stage III/IV melanoma at ESMO 2023
Checkmark Data from CheckMate -238 trial in resected stage III/IV melanoma at ESMO 2019
Sep 2019 - Sep 2019: Data from CheckMate -238 trial in resected stage III/IV melanoma at ESMO 2019
Checkmark In patients with resected stage III or IV melanoma
Jun 2018 - Jun 2018: In patients with resected stage III or IV melanoma
More
Active, not recruiting
3
906
Europe, Canada, Japan, US, RoW
Ipilimumab, Nivolumab, Placebo matching Ipilimumab, Placebo matching Nivolumab
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Melanoma
11/18
10/24
E1609, NCT01274338 / 2011-004257-29: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Checkmark From E1609 study for resected high-risk melanoma
Mar 2020 - Mar 2020: From E1609 study for resected high-risk melanoma
Checkmark Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Dec 2019 - Dec 2019: Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Checkmark From 029 study for melanoma at ASCO 2014
More
Active, not recruiting
3
1673
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI), Bristol-Myers Squibb, National Cancer Institute
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/19
03/25
CheckMate 143, NCT02017717 / 2013-003738-34: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Checkmark Data from CheckMate-143 trial vs bevacizumab in 2L glioblastoma
May 2020 - May 2020: Data from CheckMate-143 trial vs bevacizumab in 2L glioblastoma
Checkmark From CheckMate-143 trial in 2L glioblastoma
Jun 2017 - Jun 2017: From CheckMate-143 trial in 2L glioblastoma
Checkmark ASCO 2016
More
Active, not recruiting
3
529
Europe, US, RoW
Nivolumab, BMS-936558, Bevacizumab, Avastin, Ipilimumab, Yervoy
Bristol-Myers Squibb
Recurrent Glioblastoma
06/19
04/24
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
Lung-Map Sub-Study, NCT02785952: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Active, not recruiting
3
275
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
12/19
04/25
CheckMate 9ER, NCT03141177 / 2017-000759-20: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Hourglass Jun 2023 - Jun 2023 : 3 year quality-of-life follow-up data from CheckMate -9ER trial in 1L RCC at ASCO 2023
Checkmark Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Jun 2022 - Jun 2022: Data from CheckMate 9ER trial in combination with Cabometyx/Yervoy in 1L RCC at IKCS 2022
Checkmark Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
Jun 2022 - Jun 2022: Exploratory analysis data in combination with Opdivo vs sunitinib for advanced 1L RCC based on CheckMate 9ER study at ASCO 2022
More
Active, not recruiting
3
701
Europe, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Cabozantinib, Cabometyx, Sunitinib, Sutent, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb, Exelixis, Ono Pharmaceutical Co. Ltd
Renal Cell Carcinoma
02/20
04/24
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
CheckMate 649, NCT02872116 / 2016-001018-76: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Checkmark Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from Checkmate-649 trial in advanced or metastatic gastric or gastroesophageal junction cancer at ASCO-GI 2023
Checkmark From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Apr 2021 - Apr 2021: From CheckMate-649 study in combination with chemo in the Chinese subgroup of adv/mets gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Checkmark Data from Checkmate-649 trial in combination with Yervoy for advanced or metastatic gastric or gastroesophageal junction cancer at ESMO 2020
More
Active, not recruiting
3
2031
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
05/20
05/24
2019-002790-58: A study of nivolumab and ipilimumab in combination with Transarterial ChemoEmbolization (TACE) in participants with intermediate stage liver cancer (CheckMate 74W)

Not yet recruiting
3
765
Europe, RoW
NIVOLUMAB - 10mL vial (COMMERCIAL), NIVOLUMAB - 4mL vial (COMMERCIAL), IPILIMUMAB (200mg / 40ml vial), IPILIMUMAB (50mg / 10ml vial), BMS-936558, BMS-734016, Concentrate for solution for infusion, Opdivo (100 mg/10 ml), Opdivo (40 mg/4 ml)
Bristol-Myers Squibb International Corporation, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation
Intermediate-stage Hepatocellular Carcinoma (HCC), Intermediate-stage Liver Cancer, Diseases [C] - Cancer [C04]
 
 
2020-002821-28: Study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype Etude d'efficacité du nivolumab + ipilimumab versus pazopanib seul chez des patients atteints d’un sous-type rare de sarcome avancé non résécable ou métastatique

Not yet recruiting
3
96
Europe
Nivolumab, Ipilimumab, Pazopanib, Solution for injection, Film-coated tablet, Opdivo, Yervoy, Votrient
Centre Léon Bérard, BMS
Metastatic or unresectable advanced rare sarcomas Sarcomes rares avancés non résécables ou métastatiques, Metastatic advanced rare sarcomas Sarcomes rares avancés métastatiques, Diseases [C] - Cancer [C04]
 
 
CheckMate 648, NCT03143153 / 2016-001514-20: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Checkmark Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Checkmark Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
May 2022 - May 2022: Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
Checkmark Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for 1L ESCC based on Checkmate-648 trial
More
Active, not recruiting
3
970
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558 (Nivolumab), Opdivo (Nivolumab), Ipilimumab, BMS-734016 (Ipilimumab), Yervoy (Ipilimumab), Cisplatin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Various Advanced Cancer
01/21
01/25
eNERGY, NCT03351361 / 2017-002842-60: Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

Completed
3
217
Europe
Nivolumab + Ipilimumab, Chemotherapy
Rennes University Hospital
Advanced Non Small Cell Lung Cancer
07/21
07/22
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
COSMIC-313, NCT03937219 / 2018-004567-31: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Feb 2023 - Dec 2023: Overall survival analysis data from COSMIC-313 trial in combination with opdivo and yervoy for advanced 1L RCC
Checkmark Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Sep 2022 - Sep 2022: Top-line data from COSMIC-313 trial in combination with Opdivo and Yervoy for 1L RCC at ESMO 2022
Checkmark Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
Sep 2022 - Sep 2022: Detailed results from COSMIC-313 trial in combination with Opdivo and Yervoy for RCC
More
Active, not recruiting
3
840
Europe, Canada, US, RoW
Cabozantinib, Cabometyx, XL184, Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Cabozantinib-matched placebo
Exelixis
Renal Cell Carcinoma
01/22
03/25
NCT02278887 / 2013-005406-54: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Active, not recruiting
3
168
Europe
Translational research, tumor tissue, blood, Cyclophosphamide, chemotherapy, Fludarabine, Interleukin-2, Proleukin, Ipilimumab infusion, standard treatment
The Netherlands Cancer Institute, Copenhagen University Hospital at Herlev
Metastatic Melanoma
09/22
06/27
EMPOWER-Lung 3, NCT03409614 / 2017-001311-36: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Oct 2022 - Oct 2022: Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Checkmark OS and PFS data from trial for NSCLC at ESMO 2021
Sep 2021 - Sep 2021: OS and PFS data from trial for NSCLC at ESMO 2021
Checkmark From trial for NSCLC
More
Active, not recruiting
3
790
Europe, US, RoW
REGN2810, cemiplimab, REGN2810/chemo/ipi, Chemotherapy, Placebo
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer
02/25
02/25
CheckMate 914, NCT03138512 / 2016-004502-34: A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

Calendar Jan 2024 - Dec 2024: Data readout from part B of CheckMate 914 trial in combination with Yervoy for adjuvant RCC
Hourglass Sep 2023 - Mar 2024 : H2 FY'23 - Filing in Japan in combination with Yervoy for adjuvant RCC based on CheckMate-914 trial
Hourglass Jan 2022 - Dec 2022 : Regulatory submission in Japan in combination with Opdivo for adjuvant RCC (based on CheckMate-914 trial)
Checkmark Data from CheckMate 914 trial in combination with Yervoy for adjuvant RCC at ESMO 2022
Sep 2022 - Sep 2022: Data from CheckMate 914 trial in combination with Yervoy for adjuvant RCC at ESMO 2022
More
Completed
3
1653
Europe, Canada, Japan, US, RoW
nivolumab, Opdivo, ipilimumab, Yervoy, nivolumab placebo, ipilimumab placebo
Bristol-Myers Squibb
Carcinoma, Renal Cell
09/23
02/24
SWOG S1404, NCT02506153: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Active, not recruiting
3
1345
Europe, Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
09/23
01/25
DICIPLE, NCT03469960 / 2017-002540-33: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Active, not recruiting
3
265
Europe
Ipilimumab, Nivolumab
Intergroupe Francophone de Cancerologie Thoracique
Non-Small Cell Lung Cancer Metastatic
11/23
12/24
CheckMate 74W, NCT04340193: A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Terminated
3
26
Europe, Canada, Japan, US, RoW
nivolumab, Opdivo, BMS-936558, ipilimumab, Yervoy, TACE
Bristol-Myers Squibb
Cancer, Hepatocellular
12/23
12/23
CheckMate 901, NCT03036098 / 2016-003881-14: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Calendar Jan 2024 - Dec 2024: Data readout from CheckMate 901 trial in combination with Yervoy for cis-ineligible 1L urothelial cancer
Mar 2023 - Mar 2024: Submission in Japan in combination with chemotherapy for 1L urothelial cancer (based on CheckMate-901 trial)
Hourglass Jan 2023 - Dec 2023 : Submission in Japan in combination with Opdivo for 1L urothelial cancer (based on CheckMate-901 trial)
Feb 2023 - Dec 2023: Data readout from CheckMate 901 trial in combination with Yervoy for cis-eligible 1L urothelial cancer
Hourglass Oct 2023 - Oct 2023 : OS and PFS data from P3 CheckMate-901 trial in 1L unresectable or metastatic urothelial carcinoma at ESMO 2023
More
Active, not recruiting
3
1290
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Gemcitabine, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urothelial Cancer
10/24
06/28
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
CA209-8Y8, NCT03873402 / 2018-004695-35: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Hourglass Jul 2022 - Dec 2022 : Data readout from P3 CA209 -8Y8 trial for 1L RCC
Active, not recruiting
3
437
Europe, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Ipilimumab placebo
Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
03/25
IMSTAR-HN, NCT03700905 / 2016-004758-13: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Active, not recruiting
3
276
Europe
Surgical resection of primary tumor, Adjuvant radio(-chemo)therapy, Neoadjuvant Nivolumab, Adjuvant Nivolumab, Adjuvant Nivolumab and Ipilimumab
Universitätsklinikum Hamburg-Eppendorf, University Hospital, Essen, Westpfalz-Clinical Center GmbH, Charite University, Berlin, Germany
Head and Neck Cancer
05/24
05/24
CheckMate 227, NCT02477826 / 2014-003630-23: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Checkmark Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Checkmark From CheckMate 227 trial in combination with Yervoy for NSCLC at ASCO 2021
More
Active, not recruiting
3
2748
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non-Small Cell Lung Cancer
08/24
08/24
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/24
09/24
DREAMseq, NCT02224781: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Active, not recruiting
3
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib Dimethyl Sulfoxide, Mekinist, Meqsel
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
12/24
12/24
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
CheckMate 8HW, NCT04008030 / 2018-000040-26: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Calendar Jan 2024 - Dec 2024: Data readout from P3 CheckMate 8HW trial for 1L+ MSI High CRC
Jan 2023 - Dec 2023: Submission in Japan in combination with Yervoy for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Jan 2023 - Dec 2023: Submission in Japan in combination with Opdivo for 1L colorectal cancer (based on CHECKMATE 8HW trial)
Recruiting
3
831
Europe, Canada, Japan, US, RoW
Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Metastatic Colorectal Cancer
06/25
06/26
CheckMate 73L, NCT04026412 / 2019-001222-98: A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Calendar Jan 2025 - Dec 2025: Data from CheckMate73L trial in combination with Yervoy and Imfinzi for unresectable stage III NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Active, not recruiting
3
888
Europe, Canada, Japan, US, RoW
nivolumab, ipilimumab, durvalumab
Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
LONESTAR, NCT03391869: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recruiting
3
400
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Local Consolidation Therapy, LCT, Local Consolidative Therapy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
12/25
12/25
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Recruiting
3
190
Europe
Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment
ETOP IBCSG Partners Foundation, USZ Foundation
Non-Small Cell Lung Cancer, Melanoma
01/26
12/26
CheckMate 9DW, NCT04039607 / 2019-000252-34: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Calendar Jan 2025 - Dec 2025: Data readout from CheckMate 9DW trial for 1L HCC
Hourglass Jan 2020 - Jun 2020 : Submission in Japan for 2L ovarian cancer
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Nivolumab, Ipilimumab, Sorafenib, lenvatinib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Hepatocellular Carcinoma
09/26
09/26
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting
3
626
Japan, RoW
ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium
Ono Pharmaceutical Co. Ltd
Gastric Cancer
02/27
05/27
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
2019-003454-83: Does adding double immunotherapy to the combination of chemotherapy and radiotherapy result in a better anti-tumor efficacy?

Ongoing
2/3
29
Europe
Concentrate and solvent for solution for injection/infusion, , Ipilimumab, nivolumab
Amsterdam UMC, VU University Medical Center, BMS
locally advanced non-small cell lung cancer, lung cancer which is confined to the chest on 1 side and which has not spread to the rest of the body, Diseases [C] - Cancer [C04]
 
 
CA209-9HX, NCT03879122 / 2017-004377-13: A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting
2/3
135
Europe
Ipilimumab 5 MG/ML, YERVOY, Nivolumab 10 MG/ML, Opdivo, Docetaxel, ADT (androgen deprivation therapy)
Spanish Oncology Genito-Urinary Group, Syntax for Science, S.L, Bristol-Myers Squibb
Metastatic Hormone-sensitive Prostate Cancer
07/23
12/24
NCT04887870: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Active, not recruiting
2/3
55
US
Sitravatinib, MGCD516, Nivolumab, OPDIVO, Pembrolizumab, KEYTRUDA, Enfortumab Vedotin-Ejfv, PADCEV, Ipilimumab, YERVOY
Mirati Therapeutics Inc.
Advanced or Metastatic Solid Malignancies
04/25
04/25
NRG-BN007, NCT04396860: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Active, not recruiting
2/3
159
US
Contrast-enhanced Magnetic Resonance Imaging, CONTRAST ENHANCED MRI, Contrast-enhanced MRI, MRI With Contrast, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, NovoTTF-100A Device, NovoTTF-100A, NovoTTF-100A System, NovoTTF-100A system (Optune), NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI), NRG Oncology
Gliosarcoma, MGMT-Unmethylated Glioblastoma
04/23
03/25
FFCD 2101-PRODIGE 81, NCT05665348: Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Not yet recruiting
2/3
574
Europe
Ipilimumab Injection, Atezolizumab, Bevacizumab, Atezolizumab Injection
Federation Francophone de Cancerologie Digestive
HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
09/24
04/26
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT04929041: Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Recruiting
2/3
427
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/27
12/27
NCT02339571: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting
2/3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Elastography, MRE, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/33
06/33
NCT03755739: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Recruiting
2/3
200
RoW
Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy, Checkpoint inhibitor (CPI) such as Keytruda plus chemotherapy
Second Affiliated Hospital of Guangzhou Medical University
Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer
11/33
11/36
NLG-0304, NCT02054520: Immunotherapy Study for Patients With Stage IV Melanoma

Terminated
2b
47
US
HyperAcute®-Melanoma (HAM) Immunotherapy, HyperAcute®-Melanoma, HAM, Dorgenmeltucel-L, Ipilimumab, YERVOY, MDX-010, MDX-101, Pembrolizumab, Keytruda, Nivolumab, Opdivo
NewLink Genetics Corporation
Stage IV Melanoma, Metastatic Melanoma
04/18
01/21
NCT04203901: Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Terminated
2b
16
US
CMN-001, Nivolumab+Ipilimumab, Lenvatinib+Everolimus
CoImmune
Advanced Renal Cell Carcinoma
09/23
09/23
2020-001240-25: A phase II trial to study the effectivity of combination immunotherapy in patients with prostate cancer (INSPIRE) Een fase II studie om de effectiviteit van combinatie immuuntherapie te onderzoeken bij patiënten met prostaatkanker (INSPIRE)

Not yet recruiting
2
75
Europe
Nivolumab, Ipilimumab, BMS-936558, EU/1/11/698/001-002, Concentrate for solution for infusion, Opdivo, Yervoy
Radboudumc, Bristol-Myers Squibb International Corporation
(metastatic) castration-resistant prostate cancer, (metastatic) castration-resistant prostate cancer, Diseases [C] - Cancer [C04]
 
 
jRCT2080225304: Phase II study of nivolumab in combination with low-dose ipilimumab as first-line treatment in patients with advanced gastric cancer or esophagogastric junction cancer with MSI-H

Completed
2
28
Japan
Opdivo (nivolumab) - Ono Pharma, BMS, Yervoy (ipilimumab) - Ono Pharma, BMS
Kindai University Hospital, Bristol-Myers Squibb Company
Advanced gastric or esophago-gastric junction MSI-H tumor
 
 
NCT01134614: Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Checkmark ASCO 2013
Jun 2013 - Jun 2013: ASCO 2013
Active, not recruiting
2
245
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
02/13
03/25
NCT01879306: Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma

Recruiting
2
176
US
paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody, MDX-010, MDX-CTLA-4, monoclonal antibody CTLA-4, laboratory biomarker analysis, pharmacological study, pharmacological studies
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Stage IV Melanoma
06/15
 
2012-003616-31: Uptake of 89Zr-labeled ipilimumab measured with PET-scan in patients who are treated with ipilimumab Opname meting van 89Zr-gelabeld ipilimumab met behulp van PET-scan bij patiënten die behandeld worden met ipilimumab

Ongoing
2
29
Europe
ipilimumab-zirconium-89, 89Zr-ipilimumab, Solution for injection/infusion in pre-filled syringe
VU medical center, VU medical center
Advanced melanoma, Skincancer, Diseases [C] - Cancer [C04]
 
 
2015-002058-11: RIMMEL STUDY: Radiotherapy and ipilimumab in melanoma. Phase II clinical trial in patients with metastatic melanoma STUDIO RIMMEL: Radioterapia e Ipilimumab nel MELanoma. Sperimentazione clinica di Fase II in pazienti con melanoma metastatico

Not yet recruiting
2
56
Europe
ipilimumab, Concentrate for solution for injection, YERVOY - 5 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 10 ML 1 FLACONCINO
CENTRO DI RIFERIMENTO ONCOLOGICO, Centro Riferimento Oncologico
metastatic melanoma melanoma metastatico, metastatic melanoma melanoma metastatico, Diseases [C] - Cancer [C04]
 
 
2011-004200-38: A study to find out whether treating patients who have liver metastases from eye melanoma with radiofrequency ablation combined with ipilimumab, will kill the tumor without them having too many adverse events.

Ongoing
2
38
Europe
Yervoy, Yervoy
NKI-AVL, NKI-AVL, Bristol Myers-Squib
Unresectable uveal melanoma liver metastasis
 
 
2016-001883-12: Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic or Biliary tract Cancer Patients

Ongoing
2
160
Europe
Nivolumab, ipilimumab, BMS-936558, Concentrate for solution for infusion, Opdivo®, Yervoy®
Herlev & Gentofte Hospital, Oncology Dept., Oncology dept. Herlev & Gentofte Hospital, Bristol-Myers Squibb
Patients with metastatic pancreatic cancer or metastatic biliary tract cancer, Patients with metastatic pancreatic cancer or metastatic biliary tract cancer, Diseases [C] - Cancer [C04]
 
 
NCT01676649: Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
2
30
Canada
Ipilimumab, YERVOY, Carboplatin, Paclitaxel
Jewish General Hospital
Untreated Stage III Melanoma or Stage IV Melanoma
02/17
05/26
ACTRN12614001315606: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases (ABC - Anti-PD1 Brain Collaboration Study)

Active, not recruiting
2
75
 
Melanoma Institute Australia , Melanoma Institute Australia
Melanoma Brain Metastases, Melanoma
 
 
2016-003946-99: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood Estudio multicéntrico, fase 2 de nivolumab en combinación con ipilimumab para pacientes con tumores pediátricos sólidos avanzados del adulto

Ongoing
2
98
Europe
Nivolumab, Concentrate for solution for infusion, Opdivo, Yervoy
Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI), Bristol Mayer
Pediatric solid tumors presenting in adulthood Tumores pediátricos sólidos avanzados del adulto, Pediatric solid tumors presenting in adulthood Tumores pediátricos sólidos avanzados del adulto, Diseases [C] - Cancer [C04]
 
 
NCT01708941: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Active, not recruiting
2
88
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
08/17
03/25
2016-004091-21: Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature

Not yet recruiting
2
35
Europe
OPDIVO, YERVOY, Concentrate for solution for injection, OPDIVO, YERVOY
University College London, Bristol-Myers Squibb
Metastatic castrate resistant prostate cancer (prostate adenocarcinoma), Prostate cancer that has spread to other parts of the body that continues to grow and spread despite using hormone therapy (anti-androgen therapy)., Diseases [C] - Cancer [C04]
 
 
ABC, NCT02374242 / ACTRN12614001315606: Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Active, not recruiting
2
76
RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Melanoma, Brain Metastases
09/17
12/28
2017-001476-33: A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Ongoing
2
189
Europe
Yervoy, OPDIVO, BMS-734016, BMS-936558, Sterile concentrate, Yervoy, OPDIVO
University of Leeds, Bristol Myers Squibb
Previously untreated metastatic clear cell renal cell carcinoma., Previously untreated metastatic clear cell renal cell carcinoma., Diseases [C] - Cancer [C04]
 
 
2017-002442-72: RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab.

Ongoing
2
57
Europe
Ipilimumab, nivolumab, Solution for infusion, YERVOY, OPDIVO
GERCOR, Bristol-Myers Squibb
Patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab, patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab, Diseases [C] - Cancer [C04]
 
 
2017-003280-35: AMENDMENT TITLE: Phase I clinical trial on intratumoral administration of own non manipulated cells plus ipilimumab and AS01 in combination with intravenously administered nivolumabAMENDMENT 5 TITLE: A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ myeloid dendritic cells.

Not yet recruiting
2
18
Europe
CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC, Adjuvant system 01, Yervoy, Opdivo, L01XC11, L01XC17, Suspension for injection, Solution for injection, Powder and suspension for suspension for injection, Powder and solvent for solution for infusion, Yervoy, Opdivo
UZ Brussel, UZ Brussel
Patients with injectable metastases from histologically confirmed solid tumors who have failed standard-of-care life prolonging therapeutic options will be invited to participate in this clinical trial. Advanced solid tumors, progressive after standard of care., Gevorderde solide tumoren, progressief na standaard behandeling Patients with injectable metastases from solid tumors who have failed standard-of-care life prolonging therapeutic options will be invited to participate in this clinical trial., Diseases [C] - Cancer [C04]
 
 
NCT02403778: Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Completed
2
10
US
VESANOID, ATRA, Tretinoin, Ipilimumab, IPI
University of Colorado, Denver
Melanoma
08/18
01/23
2017-004780-13: Trial to investigate whether the addition of nivolumab or nivolumab and ipilimuab to rucaparib improves effectiveness, compared with rucaparib alone, in patients with relapsed ovarian cancer.

Ongoing
2
252
Europe
rucaparib, nivolumab, ipilimumab, Tablet, Concentrate for solution for infusion, nivolumab, ipilimumab
NHS Greater Glasgow & Clyde, University of Glasgow
High grade serous ovarian cancer (includes histologically identical fallopian tube and primary peritoneal cancers and high grade G3 endometrioid histological subtypes), Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
NRG-GY003, NCT02498600: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
100
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI), NRG Oncology
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
09/18
12/24
NCT02428192: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
20
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
09/18
03/25
2018-000095-15: A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma

Ongoing
2
120
Europe
Yervoy, Temodal, Concentrate for solution for injection/infusion, Capsule, Yervoy, Temodal
University of Oxford, The National Brain Appeal, Bristol-Myers Squibb, University College London Hospitals Charity
Glioblastoma, Glioblastoma is a type of brain cancer, Diseases [C] - Cancer [C04]
 
 
2017-003151-34: Clinical trial evaluating the benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Essai évaluant le bénéfice clinique d’un traitement post-opératoire associant radiothérapie + Nivolumab + Ipilimumab versus radiothérapie + Capécitabine chez des patientes atteintes d’un cancer du sein triple négatif et présentant une maladie résiduelle après chimiothérapie néoadjuvante.

Not yet recruiting
2
98
Europe
Nivolumab, Ipilimumab, Capecitabine, Solution for infusion, Solution for injection, Film-coated tablet, Opdivo, Yervoy, Capecitabine
Centre Léon Bérard, Bristol-Myers Squibb
Triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy Cancer du sein triple négatif et présentant une maladie résiduelle après chimiothérapie néoadjuvante, Breast cancer Cancer du sein, Diseases [C] - Cancer [C04]
 
 
2018-002172-40: Ipilimumab in combination with Nivolumab followed by Nivolumab monotherapy in patients with unresectable or oligometastatic melanoma. Ipilimumab in combinazione con Nivolumab seguito da Nivolumab in monoterapia nei pazienti affetti da Melanoma localmente avanzato o oligometastatico.

Ongoing
2
35
Europe
OPDIVO, YERVOY, [BMS-936558], [BMS-734016], Concentrate for solution for infusion
ISTITUTO EUROPEO DI ONCOLOGIA, Bristol Myers Squibb Pharma
Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma. Pazienti con melanoma stadio IIIB-IV, stadiazione AJCC (8 ° ed.), oligometastatico e resecabile., Patients with oligometastatic resectable melanoma Pazienti affetti da melanoma oligometastatico e resecabile., Diseases [C] - Cancer [C04]
 
 
2018-004299-37: NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in metastatic colorectal cancer. Trattamento di combinazione con NIVOLUMAB, IPILIMUMAB e TEMOZOLOMIDE in pazienti con carcinoma del colon-retto metastatico.

Ongoing
2
100
Europe
Nivolumab, Ipilimumab, Temozolomide, [-], [BMS-734016], Concentrate for solution for infusion, Capsule, hard, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 10 ML- 1 FLACONCINO, YERVOY - 5 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 40 ML 1 FLACONCINO, TEMOZOLOMIDE
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Bristol-Myers Squibb, Sun Pharmaceutical Industries Europe B.V.
Microsatellite stable (MSS), MGMT-silenced metastatic colorectal carcinoma (mCRC). Carcinoma del colon-retto metastatico (mCRC) con microsatelliti stabili (MSS) ed MGMT silenziato., Metastatic colorectal cancer (mCRC). Carcinoma del colon-retto metastatico (mCRC)., Diseases [C] - Cancer [C04]
 
 
NIPICOL, NCT03350126: iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active, not recruiting
2
57
Europe
Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML
GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb
Metastatic Cancer Colorectal
02/19
12/23
BrUOG 324, NCT02656706: Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Active, not recruiting
2
22
US
Ipilumumab, Nivolumab
Brown University, Rhode Island Hospital, The Miriam Hospital
Melanoma
03/19
07/24
NCT02500797: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Completed
2
164
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
04/19
04/23
ACTRN12618000918224: Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Completed
2
50
 
NHMRC Clinical Trials Centre, European Thoracic Oncology Platform
Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
 
 
2017-000220-10: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients With metastatic hormone receptor positive breast cancer

Ongoing
2
75
Europe
Yervoy, Opdivo, Caelyx, Sendoxane, Solution for infusion, Tablet, Yervoy (ipilimumab), Opdivo (nivolumab), Caelyx (Pegylated liposomal doxorubicin), Sendoxande (cyclophosphamide)
Oslo University Hospital, Bristol-Myers Squibb
Metastatic hormone receptor positive breast cancer (primary or recurrent), defined as ER+ >1% in metastatic biopsy (archival material or study biopsy) and HER2 negative in the last biopsy evaluable for HER2., Hormone receptor positive breast cancer, Diseases [C] - Cancer [C04]
 
 
2018-004712-22: Peri-operative association of immunotherapy in oeso-gastric adenocarcinoma

Not yet recruiting
2
32
Europe
nivolumab, ipilimumab, Solution for infusion, OPDIVO, YERVOY
GERCOR, Bristol Myers Squibb
oeso-gastric adenocarcinoma, oeso-gastric adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
NCT02919683: Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Checkmark In combination with Opdivo in 1L oral cavity squamous cell carcinoma
Aug 2020 - Aug 2020: In combination with Opdivo in 1L oral cavity squamous cell carcinoma
Checkmark In combination with Yervoy in 1L oral cavity squamous cell carcinoma
Aug 2020 - Aug 2020: In combination with Yervoy in 1L oral cavity squamous cell carcinoma
Checkmark In combination with Yervoy for resectable oral cavity cancer
More
Active, not recruiting
2
30
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Standard of Care Surgery
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Head and Neck Cancer
07/19
12/24
2018-003461-34: A phase 2 trial for patients with metastatic prostate cancer to study treatment with nivolumab and ipilimumab with or without radiotherapy Et fase 2 forsøg for patienter med spredning af prostatakræft som behandles med nivolumab og ipilimumab med eller uden strålebehandling

Not yet recruiting
2
90
Europe
Nivolumab, Ipilimumab, Concentrate for solution for infusion, Opdivo, Yervoy
Department of Oncology, Herlev & Gentofte Hospital, Department of Oncology, Herlev & Gentofte Hospital, Bristol-Myers Squibb, Varian
metastatic castration-resistant prostate cancer, metastatic prostate cancer for which hormone therapy is no longer effective, Diseases [C] - Cancer [C04]
 
 
2017-003556-23: Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy (PROMIT) Präkonditionierung von Tumor, Tumormikromilieu und Immunsysten für Immuntherapie

Not yet recruiting
2
38
Europe
Opdivo, Yervoy, Pembrolizumab, Powder and solvent for solution for infusion, Concentrate for solution for infusion, Detimedac, Opdivo, Yervoy, Keytruda
University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg, Deutsche Krebshilfe, University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg
Melanoma, Skin cancer, Diseases [C] - Cancer [C04]
 
 
NCT01585194: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Completed
2
67
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
12/19
05/24
2018-004562-33: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)

Not yet recruiting
2
194
Europe
Concentrate and solvent for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, YERVOY, OPDIVO
University Heidelberg, Med. Fac. repr. by University Hospital and its Commercial Managing Director, Bristol-Myers-Squibb
Cancer of unknown primary site (CUP-Syndrome), relapsed/refractory to platinum-based chemotherapy, Cancer of unknown primary site (CUP-Syndrome), relapsed/refractory to platinum-based chemotherapy, Diseases [C] - Cancer [C04]
 
 
2019-003668-32: A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC

Not yet recruiting
2
36
Europe
pembrolizumab, Bavencio, CD1c(BDCA-1)+/ CD141 (BDCA-3)+myeloid dendritic cells, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Suspension for injection, Keytruda, Bavencio, Yervoy
UZ Brussel, FWO
Oligometastatic solid tumors., Oligometastatic solid tumors., Diseases [C] - Cancer [C04]
 
 
PRADO, NCT02977052 / 2016-001984-35: Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

Checkmark Data from OpACIN-neo study in combination with Yervoy for macroscopic melanoma
Jun 2020 - Jun 2020: Data from OpACIN-neo study in combination with Yervoy for macroscopic melanoma
Active, not recruiting
2
186
Europe, RoW
Ipilimumab, Nivolumab, Surgery, Blood for PBMCs, Biopsies
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/20
06/25
2016-003279-23: Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY) Fase 2 Studie met de COmbinatie van Vemurafenib en Cobimetinib in BRAF V600 gemuteerde Melanoma Patiënten om LDH te normaliseren en immunotherapie met Nivolumab en Ipilimumab te optimaliseren (COWBOY)

Not yet recruiting
2
200
Europe
Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy, Cotellic, Zelboraf
Radboudumc, Bristol-Myers Squibb International Corporation
Stage IV or unresectable stage III, BRAFV600E/K mutation positive melanoma, naïve for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy, Advanced melanoma, Diseases [C] - Cancer [C04]
 
 
2019-002026-75: Clinical research study to investigate effectiveness and safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Not yet recruiting
2
154
Europe, RoW
UV1, LEUKINE, Powder for solution for injection
Ultimovacs ASA, Ultimovacs ASA
Unresectable or Metastatic Melanoma, A melanoma not capable of being surgically removed or that has been spread to other parts of the body, Diseases [C] - Cancer [C04]
 
 
 

Download Options